Search

Your search keyword '"Axel, Heidenreich"' showing total 129 results
Start Over Author "Axel, Heidenreich" Journal journal of urology
129 results on '"Axel, Heidenreich"'

1. Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference?

Author

Heather L. Huelster, Andrew Chang, Kyle M. Rose, Marco Bandini, Maarten Albersen, Eduard Roussel, Juan Chipollini, Yao Zhu, Ding-Wei Ye, Antonio A. Ornellas, Mario Catanzaro, Laura Marandino, Filippo Pederzoli, Oliver W. Hakenberg, Axel Heidenreich, Friederike Haidl, Nick Watkin, Michael Ager, Mohamed E. Ahmed, Jeffrey R. Karnes, Alberto Briganti, Youngchul Kim, Francesco Montorsi, Andrea Necchi, and Philippe E. Spiess

Subjects
Urology
Published
2023
Full Text
View/download PDF

2. Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients

Author

Maximilian Pallauf, David D’Andrea, Frederik König, Ekaterina Laukhtina, Takafumi Yanagisawa, Morgan Rouprêt, Siamak Daneshmand, Hooman Djaladat, Alireza Ghoreifi, Francesco Soria, Kazutoshi Fujita, Stephen A. Boorjian, Aaron M. Potretzke, Andrea Mari, Mathieu Roumiguié, Alessandro Antonelli, Alberto Bianchi, Zine-Eddine Khene, John P. Sfakianos, Marcus Jamil, Joost L. Boormans, Jay D. Raman, Nico C. Grossmann, Alberto Breda, Axel Heidenreich, Francesco Del Giudice, Nirmish Singla, Shahrokh F. Shariat, Benjamin Pradere, and Urology

Subjects
SDG 3 - Good Health and Well-being, Urology
Abstract

Purpose:Treatment options for the management of upper tract urothelial cancer are based on accurate staging. However, the performance of conventional cross-sectional imaging for clinical lymph node staging (N-staging) remains poorly investigated. This study aims to evaluate the diagnostic accuracy of conventional cross-sectional imaging for upper tract urothelial cancer N-staging.Materials and Methods:This study was a multicenter, retrospective, observational study. We included 865 nonmetastatic (M0) upper tract urothelial cancer patients treated with curative intended surgery and lymph node dissection who had been staged with conventional cross-sectional imaging before surgery. We compared clinical (c) and pathological (p) N-staging results to evaluate the concordance of node-positive (N+) and node-negative (N0) disease and calculate cN-staging's diagnostic accuracy.Results:Conventional cross-sectional imaging categorized 750 patients cN0 and 115 cN+. Lymph node dissection categorized 641 patients pN0 and 224 pN+. The cN-stage was pathologically downstaged in 6.8% of patients, upstaged in 19%, and found concordant in 74%. The sensitivity and specificity of cN-staging were 25% (95% CI 20; 31) and 91% (95% CI 88; 93). Positive and negative likelihood ratios were 2.7 (95% CI 2.0; 3.8) and 0.83 (95% CI 0.76; 0.89). The area under the receiver operating characteristics curve (0.58, 95% CI 0.55; 0.61) revealed low diagnostic accuracy.Conclusions:Conventional cross-sectional imaging had low sensitivity in detecting upper tract urothelial cancer pN+ disease. However, cN+ increased the likelihood of pN+ by almost threefold. Thus, conventional cross-sectional imaging is a rule-in but not a rule-out test. Lymph node dissection should remain the standard during extirpative upper tract urothelial cancer surgery to obtain accurate N-staging. cN+ could be a strong argument for early systemic treatment.

Published
2023

3. MP73-05 PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 4-YEAR FOLLOW UP

Author

Christian Pavlovich, Scott Eggener, Michael Koch, David Penson, James Relle, Steven Raman, Yair Lotan, Jurgen Futterer, Gencay Hatiboglu, Marc Serrallach, Axel Heidenreich, Aytekin Oto, Masoom Haider, J.P. Michiel Sedelaar, Temel Tirkes, Sandeep Arora, Katarzyna Macura, Daniel Costa, Allan Pantuck, Joyce Bomers, David Bonekamp, Thorsten Persigehl, Gina Clarke, Robert Staruch, Joseph Chin, and Laurence Klotz

Subjects
Urology
Published
2023
Full Text
View/download PDF

6. MP33-01 RISK OF RESIDUAL TERATOMA AFTER COMPLETE RESPONSE FOLLOWING FIRST-LINE CHEMOTHERAPY IN MEN WITH METASTATIC NON-SEMINOMATOUS GERM CELL TUMOR AND IGCCCG INTERMEDIATE/POOR PROGNOSIS: A MULTI-INSTITUTIONAL RETROSPECTIVE COHORT STUDY

Author

Luca Antonelli, Davide Ardizzone, Praful Ravi, Christopher Sweeney, Aditya Bagrodia, Michal Mego, Sia Daneshmand, Patrizia Giannatempo, Sebastiano Nazzani, Andrea Franza, Axel Heidenreich, Pia Paffenholz, Ragheed Saoud, Scott Eggener, Matthew Ho, Nathaniel Oswald, Alexey Tryakin, Natacha Naoun, Christophe Javaud, Villejuif Cedex, Antoin Douglawi, Clint Cary, Jennifer M. King, Nabil Adra, and Christian D. Fankhauser

Subjects
Urology
Published
2023
Full Text
View/download PDF

8. MP33-18 SURGICAL AND ONCOLOGIC OUTCOMES OF SURGERY IN EARLY METASTATIC SEMINOMA: MULTI-INSTITUTIONAL RETROSPECTIVE STUDY

Author

Sanam Ladi-Seyedian, Muhannad Alsyouf, Brian Hu, Clint Cary, Timothy Masterson, Lawrence Einhorn, Nabil Adra, Stephen A. Boorjian, Christian Kollmannsberger, Anne Schuckman, Alan So, Peter Black, Aditya Bagrodia, Eila Skinner, Mehrdad Alemozaffar, Timothy Brand, Scott Eggener, Phillip Pierorazio, Kelly Stratton, Lucia Nappi, Craig Nichols, Axel Heidenreich, and Siamak Daneshmand

Subjects
Urology
Published
2023
Full Text
View/download PDF

10. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of 68 Ga-PSMA and 11 C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections

Author

Giorgio Gandaglia, Steven Joniau, Alexander Kretschmer, Alexander Buchner, A. Battaglia, Nazareno Suardi, Axel Heidenreich, Andrea B. Galosi, Hendrik Van Poppel, Shahrokh F. Shariat, Francesco Montorsi, Luca Boeri, Derya Tilki, Peter Albers, Daniar Osmonov, Simone Scarcella, David Pfister, Alexander Mottrie, Andreas Hiester, Nicola Fossati, Inderbir S. Gill, Alberto Briganti, Christian G. Stief, Markus Graefen, Daniele Robesti, R. Jeffrey Karnes, Klaus P. Juenemann, and Alessandro Nini

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Urology, 030232 urology & nephrology, Salvage therapy, medicine.disease, 03 medical and health sciences, Dissection, Prostate cancer, 0302 clinical medicine, medicine.anatomical_structure, Positron emission tomography, Prostate, medicine, Radiology, Tomography, business, NODAL, Lymph node
Abstract

Purpose:We compared the use of 11C-choline and 68Ga-prostate specific membrane antigen in men undergoing salvage lymph node dissection for nodal recurrent prostate cancer.Materials and Methods:The ...

Published
2020
Full Text
View/download PDF

11. PD51-11 CONCOMITANT VS STAGED LYMPHADENECTOMY IN CLINICALLY NODE-POSITIVE PENILE SQUAMOUS CELL CARCINOMA: RECURRENCE PATTERNS AND SURVIVAL OUTCOMES

Author

Heather Huelster, Marco Bandini, Oscar Brouwer, Maarten Albersen, Eduard Roussel, Hielke de Vries, Juan Chipollini, Mounsif Azizi, Yao Zhu, Ding-Wei Ye, Antonio Ornellas, Mario Catanzaro, Laura Marandino, Oliver Hakenberg, Axel Heidenreich, Friederike Haidl, Nick Watkin, Michael Ager, Mohamed Ahmed, Jeffrey Karnes, Alberto Briganti, Roberto Salvioni, Francesco Montorsi, Andrea Necchi, and Philippe Spiess

Subjects
Urology
Published
2022
Full Text
View/download PDF

12. MP48-01 HOW TO OPTIMIZE PATIENT SELECTION BEFORE SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENT PROSTATE CANCER: A NOVEL RISK STRATIFICATION TOOL

Author

Nicola Fossati, Jeffrey R. Karnes, David Pfister, Axel Heidenreich, Alexander Kretschmer, Alexander Buchner, Christian Stief, Steven Joniau, Hendrik van Poppel, Daniar Osmonov, Klaus-Peter Juenemann, Shahrokh Shariat, Andreas Hiester, Peter Albers, Derya Tilki, Markus Graefen, Inderbir S. Gill, Elio Mazzone, Armando Stabile, Alexander Mottrie, Giorgio Gandaglia, Andrea Gallina, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

17. MP15-07 ANALYSIS OF PERIOPERATIVE COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER BASED ON EXTENSION OF PELVIC LYMPH NODE DISSECTION

Author

James A. Eastham, Inderbir S. Gill, Giovanni Cacciamani, Nima Nassiri, Axel Heidenreich, Walter Artibani, Francesco Montorsi, Paolo Dell'Oglio, Andre Luis de Castro Abreu, Alberto Briganti, Marissa Maas, Jeffrey Karnes, Christopher H. Evans, and George N. Thalmann

Subjects
medicine.medical_specialty, Prostate cancer, medicine.anatomical_structure, business.industry, Urology, medicine, In patient, Radiology, Dissection (medical), Perioperative, business, medicine.disease, Lymph node
Abstract

INTRODUCTION AND OBJECTIVE:While there is consensus on the importance of pelvic lymph node dissection (PLND) in the staging and management of clinically localized prostate cancer, there is controve...

Published
2021
Full Text
View/download PDF

18. PD53-10 PREDICTING LIMITED SURVIVAL FOR PATIENTS WITH PENILE CANCER UNDERGOING INGUINAL LYMPH NODE DISSECTION

Author

Maarten Albersen, Young-Chul Kim, Dingwei Ye, Mario Catanzaro, Antonio Augusto Ornellas, Alberto Briganti, Filippo Pederzoli, Oliver W. Hakenberg, Mahrukh Naqvi, Laura Marandino, Jeffrey Karnes, Mohamed E. Ahmed, Michael Ager, Nicholas H. Chakiryan, Eduard Roussel, Juan Chipollini, Axel Heidenreich, Lee A. Hugar, Nick Watkin, Roberto Salvioni, Yao Zhu, Friederike Haidl, Marco Bandini, Andrea Necchi, Francesco Montorsi, and Philippe E. Spiess

Subjects
medicine.medical_specialty, Poor prognosis, Palliative care, Squamous cell cancer, business.industry, Urology, Inguinal lymph nodes, medicine.disease, Surgery, Dissection, High morbidity, Medicine, Penile cancer, business
Abstract

INTRODUCTION AND OBJECTIVE:Patients with advanced penile squamous cell cancer (pSCC) have a poor prognosis and undergo treatments with high morbidity. Palliative care alongside treatments with cura...

Published
2021
Full Text
View/download PDF

19. MP46-03 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: THREE-YEAR FOLLOW-UP

Author

Laurence Klotz, Christian P. Pavlovich, Joseph Chin, Gencay Hatiboglu, Michael Koch, David Penson, Steven S. Raman, Aytekin Oto, Jurgen Fütterer, Marc Serrallach, James Relle, Yair Lotan, Axel Heidenreich, David Bonekamp, Masoom A. Haider, JP Michiel Sedelaar, Temel Tirkes, Sandeep S. Arora, Katarzyna J. Macura, Daniel N. Costa, Allan J. Pantuck, Joyce Bomers, Gina Clarke, Robert Staruch, and Scott Eggener

Subjects
Urology
Published
2021
Full Text
View/download PDF

20. MP40-02 THE COMBINATION OF MICRORNA-371A-3P AND 375-5P CAN DISTINGUISH VIABLE GERM CELL TUMOR AND TERATOMA FROM NECROSIS IN POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION SPECIMENS

Author

Lara Kremer, Martin Hellmich, Barbara Koeditz, Tim Nestler, David G. Pfister, Maike Wittersheim, Axel Heidenreich, Pia Paffenholz, and Melanie von Brandenstein

Subjects
Pathology, medicine.medical_specialty, Necrosis, business.industry, Urology, medicine.medical_treatment, medicine.disease, Retroperitoneal lymph node dissection, medicine.anatomical_structure, microRNA, medicine, Teratoma, medicine.symptom, business, Germ cell
Published
2021
Full Text
View/download PDF

21. MP15-10 THE ROLE OF LYMPH NODE DISSECTION IN PATIENTS UNDERGOING SALVAGE RADICAL PROSTATECTOMY

Author

Shahrokh F. Shariat, Abdulmajeed Aydh, Ekaterina Laukhtina, Paolo Gontero, Keiichiro Mori, Benjamin Pradere, Alberto Briganti, Pawel Rajwa, Fahad Quhal, Reza Sari Motlagh, Nico C. Grossmann, Pierre I. Karakiewicz, Hadi Mostafai, Satoshi Katayama, Romain Mathieu, and Axel Heidenreich

Subjects
medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine.disease, Radiation therapy, Dissection, Prostate cancer, medicine.anatomical_structure, Medicine, In patient, Radiology, business, Lymph node
Abstract

INTRODUCTION AND OBJECTIVE:Prostate cancer (PCa) recurrence after primary radiotherapy is increasingly encountered. Radical prostatectomy is a salvage local treatment with potentially durable disea...

Published
2021
Full Text
View/download PDF

22. PD57-12 WHICH PATIENTS WITH OLIGOMETASTATIC PROSTATE CANCER SHOULD BE CONSIDERED FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY AS PART OF A MULTIMODAL TREATMENT? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL COLLABORATION

Author

Antony Pellegrino, R. Jeffrey Karnes, Alberto Briganti, Carlo Andrea Bravi, Riccardo Leni, Armando Stabile, Nicola Fossati, Bernhard Grubmüller, Giorgio Gandaglia, Simone Scuderi, Marco Moschini, Daniele Robesti, Elio Mazzone, Andrea Gallina, Shahrok Shariat, Axel Heidenreich, David G. Pfister, Andrea Necchi, Francesco Montorsi, Nazareno Suardi, Donato Cannoletta, Vito Cucchiara, and Giuseppe Fallara

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, Prostatectomy, business.industry, Urology, Internal medicine, medicine.medical_treatment, Preoperative risk, medicine, Multimodal treatment, business, medicine.disease
Abstract

INTRODUCTION AND OBJECTIVE:Cytoreductive radical prostatectomy (cRP) might be an option in oligometastatic prostate cancer (PCa). However, no preoperative risk tool is available to select candidate...

Published
2021
Full Text
View/download PDF

23. MP64-11 PROGNOSTIC IMPACT OF GLEASON GRADE AT THE MARGIN IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY

Author

Florian Janisch, Pierre I. Karakiewicz, Keiichiro Mori, Shahrokh F. Shariat, Nicola Fossati, Fahad Quhal, Ivan Lysenko, David D'Andrea, Axel Heidenreich, and Alberto Briganti

Subjects
medicine.medical_specialty, Margin (machine learning), business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine, In patient, business, Gleason grade
Published
2021
Full Text
View/download PDF

24. MP11-11 VALIDATION AND IMPLEMENTATION OF A MOBILE APP DECISION SUPPORT SYSTEM FOR QUALITY ASSURANCE OF MULTIDISCIPLINARY TUMOR BOARDS (MTD) TO OPTIMIZE MANAGEMENT OF ADVANCED TESTICULAR CANCER

Author

Thomas Elter, Axel Heidenreich, Michael Hallek, Yasemin Ural, and David G. Pfister

Subjects
Decision support system, medicine.medical_specialty, business.industry, Urology, Mobile apps, Guideline, medicine.disease, Multidisciplinary approach, medicine, Medical physics, Testis cancer, business, Quality assurance, Testicular cancer
Abstract

INTRODUCTION AND OBJECTIVE:As has been shown recently guideline-compliance is suboptimal concerning the management of testis cancer. Guideline incompliance results in significantly impaired long-te...

Published
2020
Full Text
View/download PDF

25. MP79-07 VALIDATION AND IMPLEMENTATION OF A MOBILE APP DECISION SUPPORT SYSTEM FOR QUALITY ASSURANCE OF TUMOR BOARDS. ANALYZING THE CONCORDANCE RATES FOR PROSTATE CANCER AT A MULTIDISCIPLINARY TUMOR BOARD OF A TERTIARY REFERRAL CENTRE

Author

Rabi R Datta, Yasemin Ural, Michael Hallek, David G. Pfister, Robert Kleinert, Thomas Elter, Yasemin Yilmaz, and Axel Heidenreich

Subjects
Decision support system, medicine.medical_specialty, business.industry, Urology, Concordance, Mobile apps, Cancer, Certification, medicine.disease, Prostate cancer, Multidisciplinary approach, Medicine, Medical physics, business, Quality assurance
Abstract

INTRODUCTION AND OBJECTIVE:Certified Cancer Centers are instructed to present 100% of all cases at multidisciplinary tumor boards (MTD). Discussion of standard cases limits the time of more demandi...

Published
2020
Full Text
View/download PDF

26. PD63-02 RELIABILITY OF MODERN IMAGING STUDIES FOR DETECTION AND FINAL PATHOHISTOLOGICAL STAGE IN MEN UNDERGOING RADICAL SALVAGE PROSTATECTOMY (RSP) FOR RADIORECURRENT PROSTATE CANCER (RPC)

Author

Jeff R. Karnes, Fahad Quhal, David G. Pfister, Shahrokh F. Shariat, Patricia John, and Axel Heidenreich

Subjects
medicine.medical_specialty, Prostate biopsy, medicine.diagnostic_test, business.industry, Urology, Biochemical diagnosis, medicine.disease, Prostate cancer, mental disorders, Biopsy, medicine, sense organs, Radiology, Stage (cooking), business, Salvage prostatectomy, psychological phenomena and processes, Reliability (statistics)
Abstract

INTRODUCTION AND OBJECTIVE:RPC is a biochemical diagnosis and it requires a positive prostate biopsy prior to RSP. A positive biopsy does not distinguish between locally recurrent or metastatic dis...

Published
2020
Full Text
View/download PDF

27. PD63-11 RADICAL SALVAGE PROSTATECTOMY (RSP) FOR RADIORECURRENT PROSTATE CANCER (RPCA): ONOLOGICAL AND FUNCTIONAL OUTCOME OF A LARGE CONTEMPORARY SERIES

Author

Shahrokh F. Shariat, Axel Heidenreich, Jeff R. Karnes, Fahad Quhal, Patricia John, and David G. Pfister

Subjects
Oncology, Series (stratigraphy), medicine.medical_specialty, Prostate cancer, business.industry, Urology, Internal medicine, medicine, medicine.disease, business, Outcome (game theory), Salvage prostatectomy
Published
2020
Full Text
View/download PDF

28. PD16-02 ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF CYTOREDUCTIVE RADICAL PROSTATECTOMY (CRP) IN MEN WITH METASTATIC HORMONE-NAIVE PROSTATE CANCER (MHNPCA)

Author

Nicola Fossati, Shahrokh F. Shariat, Giorgio Gandaglia, David G. Pfister, Francesco Montorsi, Jeff R. Karnes, Alberto Briganti, Axel Heidenreich, Elio Mazzone, and Bernhard Grubmüller

Subjects
Oncology, medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine.disease, Radiation therapy, Prostate cancer, Survival benefit, Internal medicine, medicine, Hormone naive, business
Abstract

INTRODUCTION AND OBJECTIVE:Whereas radiation therapy of the local primary exerts longterm survival benefit in nmhPCA with low metastatic burden, the role of cRP is still unclear. It was the purpose...

Published
2020
Full Text
View/download PDF

29. MP79-16 LONG-TERM RESULTS OF CYTOREDUCTIVE RADICAL PROSTATECTOMY IN MEN WITH HORMONE-NAIVE, LOW VOLUME METASTATIC PROSTATE CANCER(MHNPCA)

Author

David G. Pfister, Patricia John, Axel Heidenreich, and Florian Hartmann

Subjects
medicine.medical_specialty, business.industry, medicine.drug_class, Prostatectomy, Urology, medicine.medical_treatment, Apalutamide, Long term results, Androgen, medicine.disease, Low volume, Abiraterone, chemistry.chemical_compound, Prostate cancer, chemistry, medicine, Hormone naive, business
Abstract

INTRODUCTION AND OBJECTIVE:Androgen deprivation combined with apalutamide, abiraterone or docetexal represents the treatment of choice in mhnPCA. Cytoreductive radical prostatectomy (cRP) has been ...

Published
2020
Full Text
View/download PDF

30. PD16-04 RADICAL PROSTATECTOMY VERSUS RADIOTHERAPY IN M1A AND LOW VOLUME M1B PROSTATE CANCER PATIENTS: AN INDIRECT COMPARISON WITH THE STAMPEDE TRIAL ARM H

Author

Steve Joniau, David G. Pfister, Antony Pellegrino, Wouter Everaerts, Shahrokh F. Shariat, Daniele Robesti, Nicola Fossati, Charlien Berghen, Giorgio Gandaglia, Simone Scuderi, Alberto Martini, Pierre I. Karakiewicz, Giovanni Motterle, Gaëtan Devos, Giuseppe Fallara, Bernhard Grubmüller, F. Scalvi, Francesco Montorsi, Alberto Briganti, Axel Heidenreich, and Jeffrey Karnes

Subjects
Oncology, medicine.medical_specialty, Prostatectomy, business.industry, Urology, medicine.medical_treatment, urologic and male genital diseases, medicine.disease, Indirect comparison, Radiation therapy, Low volume, Androgen deprivation therapy, Prostate cancer, Survival benefit, Internal medicine, medicine, business
Abstract

INTRODUCTION AND OBJECTIVE:The STAMPEDE trial recently demonstrated a survival benefit for patients with oligometastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) plus p...

Published
2020
Full Text
View/download PDF

31. PD17-02 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: TWO-YEAR FOLLOW-UP

Author

James Relle, Yair Lotan, Laurence Klotz, Steven S. Raman, Jurgen J. Fütterer, Sandeep Arora, Temel Tirkes, Joseph L. Chin, Gregory P. Zagaja, Marc Serrallach, Aytekin Oto, Axel Heidenreich, Daniel P. Costa, Gencay Hatiboglu, Scott E. Eggener, Andrei S. Purysko, Thorsten Persigehl, Michiel Sedelaar, Michael O. Koch, Christian P. Pavlovich, Masoom A. Haider, Allan J. Pantuck, David Bonekamp, David F. Penson, and Katarzyna J. Macura

Subjects
medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, Ultrasound, medicine.disease, Ablation, MRI-Guided Transurethral Ultrasound Ablation, Prostate cancer, medicine.anatomical_structure, Prostate, medicine, Radiology, business
Abstract

INTRODUCTION AND OBJECTIVE:MRI-guided transurethral ultrasound ablation (TULSA) is a novel minimally-invasive procedure for prostate ablation. We report two-year outcomes from the pivotal TULSA-PRO...

Published
2020
Full Text
View/download PDF

32. MP76-05 VALIDATION OF THE BEST MODELS TO PREDICT PATHOHISTOLOGY IN GERM CELL TUMOR PATIENTS UNDERGOING POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION

Author

Alessandro Nini, Bettina Baeßler, David G. Pfister, Tim Nestler, Peter Albers, Pia Paffenholz, Andreas Hiester, Martin Hellmich, and Axel Heidenreich

Subjects
medicine.medical_specialty, Retroperitoneal lymph node dissection, medicine.anatomical_structure, business.industry, Urology, medicine.medical_treatment, medicine, Radiology, business, Germ cell
Published
2020
Full Text
View/download PDF

33. MP79-02 PERFORMANCE CHARACTERISTICS OF PET/CT SCAN IN MEN TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR RECURRENT PROSTATE CANCER: A PER PATIENT ANALYSIS WITH PATHOLOGICAL CONFIRMATION ACCORDING TO EACH AREA OF DISSECTION

Author

Alberto Briganti, Christian G. Stief, Klaus-Peter Juenemann, Steven Joniau, Alexander Kretschmer, Daniar Osmonov, Axel Heidenreich, Alexander Mottrie, Alexander Buchner, Shahrokh F. Shariat, Derya Tilki, Maximilian Schmautz, Giovanni Motterle, Peter Albers, Carlo Andrea Bravi, Gaëtan Devos, Inderbir S. Gill, Jeffrey Karnes, Markus Graefen, Francesco Montorsi, Andreas Hiester, Bernhard Grubmüller, Alessandro Nini, Nicola Fossati, and Hendrik Van Poppel

Subjects
medicine.medical_specialty, PET-CT, business.industry, Urology, Treatment options, Dissection (medical), medicine.disease, Prostate cancer, medicine.anatomical_structure, Medicine, Recurrent prostate cancer, Radiology, business, Pathological, Lymph node
Abstract

INTRODUCTION AND OBJECTIVE:Salvage lymph node dissection (SLND) is among possible treatment options for patients with node-recurrent prostate cancer (PCa). It is well known that preoperative imagin...

Published
2020
Full Text
View/download PDF

34. PD57-12 THE IMPACT OF PERSISTENTLY ELEVATED PSA LEVELS ON PROGRESSION AND SURVIVAL OF PATIENTS UNDERGOING CYTOREDUCTIVE RADICAL PROSTATECTOMY FOR OLIGOMETASTATIC PROSTATE CANCER

Author

David G. Pfister, Francesco Montorsi, Nicola Fossati, Daniele Robesti, Elio Mazzone, Axel Heidenreich, Aldo Rizzo, Giuseppe Fallara, Pierre I. Karakiewicz, Gabriele Sorce, Antony Pellegrino, Francesco Pellegrino, Bernhard Grubmüller, Vincenzo Mirone, Alberto Briganti, Shahrokh F. Shariat, Andrea Gallina, Vito Cucchiara, Donato Cannoletta, F. Scalvi, Jeffrey Karnes, and Giorgio Gandaglia

Subjects
medicine.medical_specialty, Prostate cancer, genetic structures, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine, business, medicine.disease, Elevated PSA
Abstract

INTRODUCTION AND OBJECTIVE:Cytoreductive radical prostatectomy (cRP) represents an option in oligo-metastatic prostate cancer (mPCa). However, the optimal multi-modal strategy of these men is unkno...

Published
2020
Full Text
View/download PDF

35. Testis Sparing Surgery for Benign Testicular Masses: Diagnostics and Therapeutic Approaches

Author

Linn Held, Pia Paffenholz, Sven H. Loosen, David Pfister, and Axel Heidenreich

Subjects
Adenomatoid Tumor, Adult, Male, medicine.medical_specialty, Adenomatoid tumor, Urology, medicine.medical_treatment, Epidermal Cyst, 030232 urology & nephrology, Malignancy, Human chorionic gonadotropin, Benign tumor, 03 medical and health sciences, 0302 clinical medicine, Testicular Neoplasms, Testis, Biomarkers, Tumor, medicine, Humans, Testosterone, Retrospective Studies, Inguinal orchiectomy, business.industry, Middle Aged, medicine.disease, Treatment Outcome, Leydig Cell Tumor, 030220 oncology & carcinogenesis, Preoperative Period, Sertoli Cell Tumor, Radiology, Germ cell tumors, Neoplasm Recurrence, Local, business, Orchiectomy, Organ Sparing Treatments, Follow-Up Studies
Abstract

Purpose: Small benign testicular masses are often misinterpreted as germ cell tumors and immediate inguinal orchiectomy is performed. We analyzed the diagnostic and therapeutic workup of testicular masses to improve preoperative stratification algorithms.Materials and Methods: We performed a retrospective, single center analysis of the records of 522 patients diagnosed with primary testicular masses of unknown malignant potential.Results: A total of 28 patients (5%) showed a primary benign tumor after resection, including Leydig cell tumors in 9 (32%), epidermoid cysts in 9 (32%), adenomatoid tumors in 8 (29%) and Sertoli cell tumors in 2 (7%). The median volume of benign tumors was significantly less than that of malignant tumors (0.75 cm3, range 0.1 to 2.1 vs 15, range 4.5–39.9, p ≤0.001). At a cutoff of 2.8 cm3 tumor volume most accurately differentiated between benign and malignant disease, and it was a predictor of malignancy with 83% sensitivity and 89% specificity (OR 1.389, 95% CI 1.035–1.864, p =...

Published
2018
Full Text
View/download PDF

36. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial

Author

Laurence Klotz, Fong Wang, D. Robert Siemens, Ping Lin, Arnauld Villers, Steve van Os, Benoit Baron, Nahla Hasabou, Simon Chowdhury, Neal D. Shore, and Axel Heidenreich

Subjects
Male, Oncology, medicine.medical_specialty, Bicalutamide, Urology, 030232 urology & nephrology, Antineoplastic Agents, Tosyl Compounds, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Double-Blind Method, Internal medicine, Nitriles, Phenylthiohydantoin, Post-hoc analysis, medicine, Humans, Enzalutamide, Anilides, Progression-free survival, Adverse effect, Aged, business.industry, Hazard ratio, Age Factors, Middle Aged, Prostate-Specific Antigen, medicine.disease, Progression-Free Survival, Prostatic Neoplasms, Castration-Resistant, Prostate-specific antigen, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Benzamides, business, medicine.drug
Abstract

Enzalutamide significantly prolonged median progression-free survival vs bicalutamide in chemotherapy naïve men with metastatic castration resistant prostate cancer in the TERRAIN (Enzalutamide versus Bicalutamide in Castrate Men with Metastatic Prostate Cancer) trial. In this post hoc analysis we investigated the influence of age on the efficacy and safety of enzalutamide vs bicalutamide in this population.Patients were randomized 1:1 to enzalutamide 160 mg per day or bicalutamide 50 mg per day. Progression-free survival, time to prostate specific antigen progression and safety were analyzed post hoc in younger (age less than 75 years) and older (age 75 years or greater) subgroups.Enzalutamide significantly reduced the risk of disease progression or death vs bicalutamide in patients younger than 75 years (HR 0.38, 95% CI 0.27-0.52, p0.0001) and 75 years old or older (HR 0.59, 95% CI 0.37-0.92, p = 0.018). Time to prostate specific antigen progression was also significantly prolonged with enzalutamide vs bicalutamide in each subgroup. The adverse event distribution between treatments was similar in each subgroup except for more (5% or greater difference between subgroups) atrial fibrillation, urinary tract infections, falls and decreased appetite as well as less extremity pain and hot flushing in enzalutamide treated patients 75 years old or older, and less back pain and hot flushing in bicalutamide treated patients 75 years old or older. Grade 3 or greater cardiac events were more frequent in enzalutamide treated and bicalutamide treated patients who were 75 years old or older vs younger than 75 years. Fatigue was more frequent in enzalutamide treated patients with a similar distribution in each age subgroup.Enzalutamide improved clinical outcomes vs bicalutamide irrespective of age. Increased falls and cardiac events suggest caution when prescribing to older patients (age 75 years or greater) with significant comorbidity.

Published
2018
Full Text
View/download PDF

37. Reply by Authors

Author

Nicholas H. Chakiryan, Aaron Dahmen, Marco Bandini, Filippo Pederzoli, Laura Marandino, Maarten Albersen, Eduard Roussel, Yao Zhu, Ding-Wei Ye, Antonio A. Ornellas, Mario Catanzaro, Oliver W. Hakenberg, Axel Heidenreich, Friederike Haidl, Nick Watkin, Michael Ager, Jad Chahoud, Alberto Briganti, Roberto Salvioni, Francesco Montorsi, Andrea Necchi, and Philippe E. Spiess

Subjects
Urology
Published
2021
Full Text
View/download PDF

38. MP28-13 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES TO PREDICT RADIORESISTANT PROSTATE CARCINOMAS

Author

Maike Wittersheim, Stephan C. Schaefer, Reinhard Büttner, Margarete Odenthal, Axel Heidenreich, Martin Hellmich, Tim Nestler, and David G. Pfister

Subjects
business.industry, Urology, medicine.medical_treatment, medicine.disease, Radiation therapy, Prostate cancer, medicine.anatomical_structure, Differentially expressed genes, Prostate, Radioresistance, Cancer research, Medicine, Identification (biology), business
Abstract

INTRODUCTION AND OBJECTIVES:Although relapses after radiotherapy are common in prostate cancer (PCa) patients, there are no clinical models or markers to identify patients at high risk for radiores...

Published
2019
Full Text
View/download PDF

39. MP22-03 LONG-TERM ONCOLOGIC OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES

Author

Akbar Ashrafi, Shahrokh F. Shariat, Daniar Osmonov, Klaus-Peter Juenemann, Inderbir S. Gill, Peter Albers, Carlo Andrea Bravi, Nazareno Suardi, Alberto Briganti, Alexander Kretschmer, Axel Heidenreich, Christian G. Stief, Derya Tilki, Andreas Hiester, Giorgio Gandaglia, Alexander Buchner, A. Battaglia, Melle Alexander Mottrie, Almut Kalz, Markus Graefen, Hein Van Poppel, Steven Joniau, R. Jeffrey Karnes, Luca Boeri, Bernhard Grubmüller, Alessandro Nini, and Nicola Fossati

Subjects
medicine.medical_specialty, Series (stratigraphy), business.industry, Urology, medicine.disease, Term (time), Dissection, Prostate cancer, medicine.anatomical_structure, Medicine, Radiology, business, NODAL, Lymph node
Abstract

INTRODUCTION AND OBJECTIVES:Salvage lymph node dissection (SLND) represents a possible treatment approach for patients affected by nodal recurrence of prostate cancer (PCa). However, its oncologica...

Published
2019
Full Text
View/download PDF

41. PD17-08 COMPARING THE DIAGNOSTIC ACCURACY OF 68GA-PSMA AND 11C-CHOLINE PET/CTSCAN ACCORDING TO PSA LEVEL: A LARGE MULTI-INSTITUTIONAL ANALYSIS WITH HISTOLOGICAL VERIFICATION IN PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR RECURRENT PROSTATE CANCER

Author

Daniar Osmonov, Akbar Ashrafi, Alexander Mottrie, Nazareno Suardi, Markus Graefen, Inderbir S. Gill, Axel Heidenreich, Alexander Kretschmer, Steven Joniau, Bernhard Grubmüller, R. Jeffrey Karnes, Alessandro Nini, Luca Boeri, Nicola Fossati, Andreas Hiester, Alberto Briganti, Almut Kalz, Christian G. Stief, Francesco Montorsi, Shahrokh F. Shariat, Peter Albers, Carlo Andrea Bravi, Hein Van Poppel, Derya Tilki, Giorgio Gandaglia, Klaus-Peter Juenemann, Alexander Buchner, and A. Battaglia

Subjects
11C-choline, medicine.medical_specialty, business.industry, Urology, Context (language use), Diagnostic accuracy, Lesion, Dissection, medicine.anatomical_structure, medicine, In patient, Recurrent prostate cancer, Radiology, medicine.symptom, business, Lymph node
Abstract

INTRODUCTION AND OBJECTIVES:Despite high specificity, PET/CT scan is limited by relatively low sensitivity at a lesion-based analysis in the context of recurrent prostate cancer (PCa). Moreover, un...

Published
2019
Full Text
View/download PDF

42. LBA-26 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER

Author

James Relle, J.P. Michiel Sedelaar, Mathieu Burtnyk, Daniel P. Costa, Allan J. Pantuck, David Bonekamp, David F. Penson, Yair Lotan, Sandeep Arora, Michael O. Koch, Steven S. Raman, Christian P. Pavlovich, Gregory P. Zagaja, Katarzyna J. Macura, Gencay Hatiboglu, Marc Serrallach, Aytekin Oto, William Li, Robert Staruch, Masoom A. Haider, Temel Tirkes, Scott E. Eggener, Jurgen J. Fütterer, Joseph L. Chin, Thorsten Persigehl, Laurence Klotz, and Axel Heidenreich

Subjects
medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, Ultrasound, 030232 urology & nephrology, medicine.disease, Ablation, MRI-Guided Transurethral Ultrasound Ablation, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, medicine.anatomical_structure, Prostate, medicine, Radiology, business
Abstract

INTRODUCTION AND OBJECTIVES:MRI-guided transurethral ultrasound ablation (TULSA) is a novel minimally-invasive procedure for customized prostate ablation. We report one-year outcomes from the TULSA...

Published
2019
Full Text
View/download PDF

43. MP73-13 COMPREHENSIVE ANALYSIS OF METASTATIC SEMINOMA GERM CELL TUMORS SHOWS DIVERGENT EXPRESSION OF IMMUNE-RELATED PATHWAYS

Author

Tim Nestler, Svenja Wagener-Ryczek, Martin Hellmich, Priya Dalvi, Maike Wittersheim, Margarete Odenthal, Friederike Haidl, Reinhard Büttner, Axel Heidenreich, Pia Paffenholz, and David G. Pfister

Subjects
Immune system, business.industry, Urology, Metastatic seminoma, Cancer research, Medicine, Germ cell tumors, business, medicine.disease
Published
2019
Full Text
View/download PDF

44. MP22-06 IMAGING TARGETED TREATMENTS VERSUS EXTENDED SALVAGE LYMPH NODE DISSECTION FOR PATIENTS WITH A SINGLE NODAL RECURRENCE OF PROSTATE CANCER: A COMPARATIVE ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES

Author

Alberto Briganti, Christian G. Stief, Giorgio Gandaglia, Thomas Zilli, David Pasquier, R. Jeffrey Karnes, Alfonso Gomez De Iturriaga, Beatrice Detti, Daniar Osmonov, Piet Ost, Nicholas van As, Inderbir S. Gill, Derya Tilki, Fabio Trippa, Alexander Mottrie, Elise De Bleser, Shankar Siva, Steven Joniau, Piet Dirix, Peter Albers, Nicola Fossati, Shahrokh F. Shariat, Barbara Alicja Jereczek-Fossa, Markus Graefen, Francesco Montorsi, Andrei Fodor, Hein Van Poppel, and Axel Heidenreich

Subjects
medicine.medical_specialty, Dissection, Series (stratigraphy), Prostate cancer, medicine.anatomical_structure, business.industry, Urology, medicine, Radiology, business, medicine.disease, NODAL, Lymph node
Abstract

INTRODUCTION AND OBJECTIVES:Extended and targeted treatment approaches have been proposed for patients affected by nodal recurrence of prostate cancer (PCa). However, a significant under-estimation...

Published
2019
Full Text
View/download PDF

45. MP49-01 PREDICTORS OF THROMBOSIS IN TESTICULAR CANCER DURING PLATINUM-BASED CHEMOTHERAPY

Author

David G. Pfister, Martin Hellmich, Katharina Grein, Salem Johannes, Pia Paffenholz, Axel Heidenreich, Isabel Heidegger, and Tim Nestler

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, endocrine system diseases, business.industry, Urology, medicine.medical_treatment, Internal medicine, medicine, medicine.disease, business, Thrombosis, Testicular cancer
Abstract

INTRODUCTION AND OBJECTIVES:Testicular cancer patients receiving platinum-based chemotherapy are at risk for the development of venous thromboembolic events. In this study, we aim to identify poten...

Published
2019
Full Text
View/download PDF

46. MP21-09 NON-INVASIVE URINE MARKERS FOR THE DIFFERENTIATION BETWEEN RCCS AND ONCOCYTOMA

Author

Sibel Cakir, Barbara Köditz, Caroline Eich, Jochen W.U. Fries, Melanie von Brandenstein, and Axel Heidenreich

Subjects
Pathology, medicine.medical_specialty, biology, business.industry, Urology, Non invasive, food and beverages, Vimentin, Urine, urologic and male genital diseases, medicine.disease, medicine, biology.protein, Oncocytoma, business
Abstract

INTRODUCTION AND OBJECTIVES:Recently our group showed that Vim3, a truncated variant of Vimentin, is overexpressed in oncocytoma and can be used as differentiating marker. Normally Vim3 is a marker...

Published
2019
Full Text
View/download PDF

47. PD56-03 INDEPENDENT VALIDATION OF TWO MODELS TO PREDICT NECROSIS/FIBROSIS IN POST CHEMOTHERAPY RESIDUAL RETROPERITONEAL MASSES OF PATIENTS WITH ADVANCED TESTICULAR CANCER

Author

Simon Hoier, Martin Hellmich, David G. Pfister, Axel Heidenreich, Tim Nestler, and Pia Paffenholz

Subjects
medicine.medical_specialty, Necrosis, Fibrosis, business.industry, Urology, medicine, medicine.symptom, Post-chemotherapy, medicine.disease, business, Testicular cancer
Published
2019
Full Text
View/download PDF

49. PD22-04 AUGMENTATION URETHRAL RECONSTUCTION USING TISSUE-ENGINEERED ORAL MUCOSA GRAFT MUKOCELL®

Author

Leonidas Karapanos, Caroline Eich, Ilgar Akbarov, Vahudin Zugor, and Axel Heidenreich

Subjects
medicine.medical_specialty, Tissue engineered, medicine.anatomical_structure, business.industry, Urology, Medicine, Oral mucosa, business, Buccal mucosa, Surgery
Abstract

INTRODUCTION AND OBJECTIVES:One-stage augmentation urethral reconstruction with buccal mucosa is the method of choice in recurrent urethral strictures and achieves good results up to 75-85% with lo...

Published
2019
Full Text
View/download PDF

50. PD25-11 MULTIVISCERAL SURGERY IN MEN WITH LOCALLY ADVANCED, SYMPTOMATIC CASTRATION RESISTANT PROSTATE CANCER

Author

Axel Heidenreich, Daniel Porres, Leonidas Karapanos, Johannes Salem, David Pfister, and Friederike Haidl

Subjects
medicine.medical_specialty, Prostate cancer, business.industry, Urology, medicine, Locally advanced, Castration resistant, urologic and male genital diseases, Urinary tract obstruction, medicine.disease, business, Gross hematuria, Surgery
Abstract

INTRODUCTION AND OBJECTIVES:Local complications such as gross hematuria and clotting, repetitive blood transfusions, upper and lower urinary tract obstruction, intestinal obstruction, and treatment...

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results